The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma

Shengjian Huang, Changying Jiang, Hui Zhang, Taylor Bell, Hui Guo, Yang Liu, Yixin Yao, Dongfeng Zeng, Makhdum Ahmed, Krystle Nomie, Leo Yu Zhang, Michael WangBlood 2018 · DOI · OpenAlex

Introduction

Mantle cell lymphoma (MCL) remains a clinical challenge due to its aggressive nature and the frequent development of resistance to standard therapies like the BTK inhibitor ibrutinib. While anti-CD20 antibodies such as rituximab are commonly used, their efficacy as monotherapy is often limited. This study evaluates MT-3724, a novel Engineered Toxin Body (ETB) designed to overcome these limitations by delivering a potent cytotoxic payload directly to CD20-positive cells.

Methods

MT-3724 is a fusion protein comprising a CD20-targeting single-chain variable fragment (scFv) and a modified Shiga-like toxin 1A (SLT-1A) subunit. Unlike standard antibody-drug conjugates, this ETB utilizes the toxin's natural ability to halt protein synthesis once internalized. The researchers tested MT-3724 across eight MCL cell lines, including the ibrutinib-resistant Jeko-R line. Efficacy was further validated in vivo using a patient-derived xenograft (PDX) mouse model derived from an ibrutinib-resistant patient. Signaling pathways were analyzed using Reverse Phase Protein Array (RPPA) to map the drug's impact on cellular signaling.

Results

Potency and Resistance Bypass

MT-3724 demonstrated significant growth inhibition across all tested MCL cell lines, with $IC_{50}$ values ranging from 78 to 1383 ng/mL. Crucially, the drug's efficacy was independent of ibrutinib sensitivity, as shown by its comparable activity in both sensitive and resistant lines (e.g., Jeko-1 vs. Jeko-R). This suggests that the mechanism of protein synthesis inhibition successfully bypasses common kinase-inhibitor resistance mutations.

Figure 1: MT-3724 demonstrates potent anti-tumor activity in vitro and in vivo. (A-C) Cell viability and IC50 values across MCL lines. (D-G) Induction of apoptosis and cell cycle arrest. (I-J) Significant reduction in tumor volume and improved survival in ibrutinib-resistant PDX models.

Mechanism of Action and In Vivo Success

The drug induced dose-dependent apoptosis, evidenced by increased caspase 3/7 expression and PARP cleavage. Furthermore, MT-3724 treatment resulted in cell cycle arrest at the G0/G1 phase. In an ibrutinib-resistant PDX model, MT-3724 treatment led to a significant reduction in tumor volume and a marked increase in overall survival compared to vehicle-treated controls ($P < 0.01$). Interestingly, sensitivity did not strictly correlate with CD20 surface density, suggesting that internalization efficiency is a critical determinant of efficacy.

Synergistic Effects

MT-3724 exhibited strong synergy when combined with ibrutinib or the BCL-2 inhibitor ABT-199 (venetoclax). The ETB appears to lower the apoptotic threshold by reducing levels of anti-apoptotic proteins like MCL-1 and BCL-2, thereby sensitizing cells to secondary agents. This synergy was particularly evident in cell lines that were otherwise resistant to single-agent treatment.

Figure 3: Synergistic effects of MT-3724 with ibrutinib (IBN) and ABT-199. (C-D, G-H) Enhanced apoptosis in Z-138, Jeko-R, and Granta519 lines when MT-3724 is combined with other inhibitors. (E-F) Relative cell viability curves showing synergistic growth inhibition.

Discussion

The findings highlight MT-3724's potential as a "molecular Trojan horse" capable of bypassing kinase-inhibitor resistance through a distinct mechanism of protein synthesis inhibition. While the Z-138 line showed relative insensitivity—possibly due to ILK and PAK signaling pathways—the overall results are highly promising. MT-3724 has entered Phase I/Ib clinical trials, which will be the ultimate test of its translational potential in patients with relapsed or refractory B-cell malignancies.

Summary updated

BibTeX
@inproceedings{huang2018cd,
  author = {Shengjian Huang and Changying Jiang and Hui Zhang and Taylor Bell and Hui Guo and Yang Liu and Yixin Yao and Dongfeng Zeng and Makhdum Ahmed and Krystle Nomie and Leo Yu Zhang and Michael Wang},
  title = {{The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma}},
  booktitle = {Blood},
  year = {2018},
  doi = {10.1038/s41408-018-0066-7},
}
Figure